Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study medication 
Has received sorafenib or oxaliplatin-based chemotherapy within 14 days of first dose of study medication 
Has had esophageal or gastric variceal bleeding within the last 6 months 
Has clinically apparent ascites on physical examination 
Has portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging 
Has had clinically diagnosed hepatic encephalopathy in the last 6 months 
Has had a solid organ or hematologic transplant 
Has had prior systemic therapy for HCC in the advanced (incurable) setting other than sorafenib or oxaliplatin-based chemotherapy, prior to start of study medication 
Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment. 
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication 
Has received locoregional therapy to liver (transcatheter chemoembolization [TACE], transcatheter embolization [TAE], hepatic arterial infusion [HAI], radiation, radioembolization, or ablation) or other site within 4 weeks prior to the first dose of study medication 
Has had major surgery to liver or other site within 4 weeks prior to the first dose of study medication 
Has had a minor surgery ≤7 days prior to the first dose of study medication 
Has not recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to study start 
Has a diagnosed additional malignancy within 3 years prior to first dose of study medication with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers 
Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis 
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis 
Has an active infection requiring systemic therapy 
Is pregnant or breast feeding or expecting to conceive or father starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication 
Has received prior immunotherapy with an anti-Programmed Cell Death Receptor 1 (PD-1), Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death Receptor Ligand 2 (PD-L2) or has previously participated in clinical studies with pembrolizumab 
Has a known history of human immunodeficiency virus (HIV) 
Has untreated active Hepatitis B 
Has hepatitis C in which participants received therapy for HCV <4 weeks prior to receiving pembrolizumab 
Has received a live vaccine within 30 days prior to the first dose of study therapy       
    

NCT03062358_exc_T2
Drug
sorafenib
NCT03062358_exc_T3
Drug
oxaliplatin
NCT03062358_exc_T4
Procedure
chemotherapy
NCT03062358_exc_T5
Qualifier
sorafenib or oxaliplatin-based
NCT03062358_exc_T6
Temporal
within 14 days
NCT03062358_exc_T7
Reference_point
first dose of study medication
NCT03062358_exc_T8
Condition
esophageal variceal bleeding
NCT03062358_exc_T9
Condition
gastric variceal bleeding
NCT03062358_exc_T10
Temporal
within the last 6 months
NCT03062358_exc_T11
Scope
esophageal or gastric variceal bleeding
NCT03062358_exc_T12
Condition
ascites
NCT03062358_exc_T13
Condition
portal vein invasion
NCT03062358_exc_T14
Qualifier
main portal branch (Vp4)
NCT03062358_exc_T15
Qualifier
inferior vena cava
NCT03062358_exc_T16
Condition
cardiac involvement
NCT03062358_exc_T17
Condition
HCC
NCT03062358_exc_T18
Procedure
imaging
NCT03062358_exc_T19
Scope
main portal branch (Vp4), inferior vena cava
NCT03062358_exc_T20
Scope
portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement
NCT03062358_exc_T21
Condition
hepatic encephalopathy
NCT03062358_exc_T22
Temporal
in the last 6 months
NCT03062358_exc_T23
Procedure
hematologic transplant
NCT03062358_exc_T24
Procedure
solid organ transplant
NCT03062358_exc_T25
Procedure
systemic therapy
NCT03062358_exc_T26
Condition
HCC
NCT03062358_exc_T27
Drug
sorafenib
NCT03062358_exc_T28
Drug
oxaliplatin
NCT03062358_exc_T29
Procedure
chemotherapy
NCT03062358_exc_T30
Qualifier
sorafenib or oxaliplatin-based
NCT03062358_exc_T31
Temporal
prior
NCT03062358_exc_T32
Reference_point
start of study medication
NCT03062358_exc_T33
Scope
systemic therapy for HCC in the advanced (incurable) setting other than sorafenib or oxaliplatin-based chemotherapy
NCT03062358_exc_T34
Temporal
active
NCT03062358_exc_T35
Condition
autoimmune disease
NCT03062358_exc_T36
Procedure
systemic treatment
NCT03062358_exc_T37
Temporal
in the past 2 years
NCT03062358_exc_T39
Condition
immunodeficiency
NCT03062358_exc_T40
Procedure
systemic steroid therapy
NCT03062358_exc_T41
Procedure
immunosuppressive therapy
NCT03062358_exc_T42
Temporal
within 7 days prior
NCT03062358_exc_T43
Reference_point
the first dose of study medication
NCT03062358_exc_T44
Scope
systemic steroid therapy or any other form of immunosuppressive therapy
NCT03062358_exc_T45
Procedure
locoregional therapy
NCT03062358_exc_T46
Procedure
transcatheter chemoembolization [TACE]
NCT03062358_exc_T47
Procedure
transcatheter embolization [TAE]
NCT03062358_exc_T48
Procedure
hepatic arterial infusion [HAI]
NCT03062358_exc_T49
Procedure
radiation
NCT03062358_exc_T50
Procedure
radioembolization
NCT03062358_exc_T51
Procedure
ablation
NCT03062358_exc_T52
Temporal
within 4 weeks prior
NCT03062358_exc_T53
Reference_point
first dose of study medication
NCT03062358_exc_T54
Qualifier
liver
NCT03062358_exc_T55
Qualifier
other site
NCT03062358_exc_T56
Scope
transcatheter chemoembolization [TACE], transcatheter embolization [TAE], hepatic arterial infusion [HAI], radiation, radioembolization, or ablation
NCT03062358_exc_T57
Procedure
major surgery
NCT03062358_exc_T58
Qualifier
liver
NCT03062358_exc_T59
Qualifier
other site
NCT03062358_exc_T60
Temporal
within 4 weeks prior
NCT03062358_exc_T61
Reference_point
first dose of study medication
NCT03062358_exc_T62
Procedure
minor surgery
NCT03062358_exc_T63
Temporal
≤7 days prior
NCT03062358_exc_T64
Reference_point
first dose of study medication
NCT03062358_exc_T68
Condition
malignancy
NCT03062358_exc_T69
Qualifier
additional
NCT03062358_exc_T70
Temporal
within 3 years prior to first dose of study medication
NCT03062358_exc_T71
Reference_point
first dose of study medication
NCT03062358_exc_T72
Procedure
treated
NCT03062358_exc_T73
Qualifier
curatively
NCT03062358_exc_T75
Condition
basal cell carcinoma of the skin
NCT03062358_exc_T76
Condition
squamous cell carcinoma of the skin
NCT03062358_exc_T77
Condition
in situ cancers
NCT03062358_exc_T78
Procedure
resected
NCT03062358_exc_T79
Qualifier
curatively
NCT03062358_exc_T80
Qualifier
curatively treated
NCT03062358_exc_T81
Qualifier
curatively resected
NCT03062358_exc_T82
Scope
curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers
NCT03062358_exc_T83
Observation
history
NCT03062358_exc_T84
Observation
evidence
NCT03062358_exc_T85
Condition
central nervous system (CNS) metastases
NCT03062358_exc_T86
Condition
carcinomatous meningitis
NCT03062358_exc_T87
Scope
central nervous system (CNS) metastases and/or carcinomatous meningitis
NCT03062358_exc_T89
Drug
steroids
NCT03062358_exc_T90
Drug
pneumonitis
NCT03062358_exc_T91
Temporal
current
NCT03062358_exc_T92
Observation
history
NCT03062358_exc_T93
Condition
non-infectious) pneumonitis
NCT03062358_exc_T88
Procedure
systemic therapy
NCT03062358_exc_T94
Temporal
active
NCT03062358_exc_T95
Condition
infection
NCT03062358_exc_T96
Qualifier
requiring systemic therapy
NCT03062358_exc_T99
Procedure
immunotherapy
NCT03062358_exc_T100
Drug
anti-Programmed Cell Death Receptor 1 (PD-1)
NCT03062358_exc_T101
Drug
Programmed Cell Death Receptor Ligand 1 (anti-PD-L1)
NCT03062358_exc_T102
Drug
anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)
NCT03062358_exc_T104
Drug
pembrolizumab
NCT03062358_exc_T105
Scope
anti-Programmed Cell Death Receptor 1 (PD-1), Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)
NCT03062358_exc_T106
Observation
participated in clinical studies with pembrolizumab
NCT03062358_exc_T107
Condition
human immunodeficiency virus (HIV)
NCT03062358_exc_T108
Observation
history
NCT03062358_exc_T109
Condition
Hepatitis B
NCT03062358_exc_T110
Qualifier
untreated
NCT03062358_exc_T111
Qualifier
active
NCT03062358_exc_T112
Condition
hepatitis C
NCT03062358_exc_T113
Procedure
therapy for HCV
NCT03062358_exc_T114
Temporal
<4 weeks prior
NCT03062358_exc_T115
Drug
pembrolizumab
NCT03062358_exc_T116
Reference_point
receiving pembrolizumab
NCT03062358_exc_T117
Condition
live vaccine
NCT03062358_exc_T118
Temporal
30 days prior
NCT03062358_exc_T119
Reference_point
first dose of study therapy
NCT03062358_exc_T120
Negation
with the exception of
NCT03062358_exc_T97
Condition
pregnant
NCT03062358_exc_T98
Observation
breast feeding
NCT03062358_exc_T121
Observation
expecting to conceive
NCT03062358_exc_T122
Observation
expecting to father
NCT03062358_exc_T123
Temporal
starting from the first dose of study medication
NCT03062358_exc_T124
Reference_point
the first dose of study medication
NCT03062358_exc_T125
Temporal
throughout the study period
NCT03062358_exc_T126
Reference_point
the study period
NCT03062358_exc_T127
Temporal
for up to 120 days after the last dose of study medication
NCT03062358_exc_T128
Reference_point
the last dose of study medication
NCT03062358_exc_T129
Scope
starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication
NCT03062358_exc_T130
Negation
other than